From: ROC-1, P21 and CAIX as markers of tumor aggressiveness in bladder carcinoma in Egyptian patients
Variables | Category | control group (n = 15) | Malignant group (n = 80) | Test of significance | p_value |
---|---|---|---|---|---|
ROC1 expression | Negative | 1 (6.66%) | 8 (10%) | FE = 0.16 | 1 |
Positive | 14 (93.33%) | 72 (90%) | |||
ROC1 Sub cellular localization | Cytoplasmic | 8 (57.14%) | 24 (33.3%) | ×2 = 2.84 | 0.09 |
Nucleocytoplasmic | 6 (42.86%) | 48 (66.7%) | |||
ROC1 H-score | Low expression | 8 (57.1%) | 37 (51.4%) | X2 = 0.16 | 0.69 |
High expression | 6 (42.9%) | 35 (48.6%) | |||
P21 expression | Negative | 5 (33.3%) | 13 (16.25%) | FE = 2.4 | 0.1 |
Positive | 10 (66.7%) | 67 (83.75%) | |||
P21 Sub cellular localization | Cystoplasmic | 8 (80%) | 55 (82.1%) | FE = 0.03 | 1 |
Nucleocytoplasmic | 2 (20%) | 12 (17.9%) | |||
P21 H-score | Low expression | 5 (50%) | 34 (50.7%) | FE = 0.002 | 1 |
High expression | 5 (50%) | 33 (49.3%) | |||
CAIX expression | Negative | 11 (26.2%) | 31 (73.8%) | x2 = 6.13 | 0.01* |
Positive | 4 (7.5%) | 49 (92.5%) | |||
CAIX Sub cellular localization | Cystoplasmic | 4 (8.3%) | 44 (91.7%) | FE = 0.45 | 1 |
Nucleocytoplasmic | 0 (0%) | 5 (100%) | |||
CAIX H-score | Low expression | 1 (3.1%) | 31 (96.9%) | FE = 0.22 | 1 |
High expression | 3 (14.3%) | 18 (85.7%) |